191 related articles for article (PubMed ID: 7625109)
1. Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes.
de Haan A; Geerligs HJ; Huchshorn JP; van Scharrenburg GJ; Palache AM; Wilschut J
Vaccine; 1995 Feb; 13(2):155-62. PubMed ID: 7625109
[TBL] [Abstract][Full Text] [Related]
2. Liposomes as an immunoadjuvant system for stimulation of mucosal and systemic antibody responses against inactivated measles virus administered intranasally to mice.
de Haan A; Tomee JF; Huchshorn JP; Wilschut J
Vaccine; 1995 Oct; 13(14):1320-4. PubMed ID: 8585287
[TBL] [Abstract][Full Text] [Related]
3. Immunopotentiation of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice.
Ben Ahmeida ET; Gregoriadis G; Potter CW; Jennings R
Vaccine; 1993 Oct; 11(13):1302-9. PubMed ID: 8296483
[TBL] [Abstract][Full Text] [Related]
4. Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal IgA production in response to the influenza virus antigen.
Mizuno D; Ide-Kurihara M; Ichinomiya T; Kubo I; Kido H
J Immunol; 2006 Jan; 176(2):1122-30. PubMed ID: 16394001
[TBL] [Abstract][Full Text] [Related]
5. Induction of a secretory IgA response in the murine female urogenital tract by immunization of the lungs with liposome-supplemented viral subunit antigen.
de Haan A; Renegar KB; Small PA; Wilschut J
Vaccine; 1995 May; 13(7):613-6. PubMed ID: 7668030
[TBL] [Abstract][Full Text] [Related]
6. IgG subclass response and protection against challenge following immunisation of mice with various influenza A vaccines.
Ben-Ahmeida ET; Potter CW; Gregoriadis G; Adithan C; Jennings R
J Med Microbiol; 1994 Apr; 40(4):261-9. PubMed ID: 8151677
[TBL] [Abstract][Full Text] [Related]
7. Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen.
Verweij WR; de Haan L; Holtrop M; Agsteribbe E; Brands R; van Scharrenburg GJ; Wilschut J
Vaccine; 1998 Dec; 16(20):2069-76. PubMed ID: 9796066
[TBL] [Abstract][Full Text] [Related]
8. alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor.
Ko SY; Ko HJ; Chang WS; Park SH; Kweon MN; Kang CY
J Immunol; 2005 Sep; 175(5):3309-17. PubMed ID: 16116223
[TBL] [Abstract][Full Text] [Related]
9. Induction of Local Secretory IgA and Multifunctional CD4⁺ T-helper Cells Following Intranasal Immunization with a H5N1 Whole Inactivated Influenza Virus Vaccine in BALB/c Mice.
Trondsen M; Aqrawi LA; Zhou F; Pedersen G; Trieu MC; Zhou P; Cox RJ
Scand J Immunol; 2015 May; 81(5):305-17. PubMed ID: 25737202
[TBL] [Abstract][Full Text] [Related]
10. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
11. Mucosal immunoadjuvant activity of liposomes: role of alveolar macrophages.
de Haan A; Groen G; Prop J; van Rooijen N; Wilschut J
Immunology; 1996 Dec; 89(4):488-93. PubMed ID: 9014811
[TBL] [Abstract][Full Text] [Related]
12. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W
Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856
[TBL] [Abstract][Full Text] [Related]
13. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
[TBL] [Abstract][Full Text] [Related]
14. Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity.
Haan L; Verweij WR; Holtrop M; Brands R; van Scharrenburg GJ; Palache AM; Agsteribbe E; Wilschut J
Vaccine; 2001 Apr; 19(20-22):2898-907. PubMed ID: 11282201
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen.
Childers NK; Miller KL; Tong G; Llarena JC; Greenway T; Ulrich JT; Michalek SM
Infect Immun; 2000 Oct; 68(10):5509-16. PubMed ID: 10992447
[TBL] [Abstract][Full Text] [Related]
16. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
[TBL] [Abstract][Full Text] [Related]
17. Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines.
Wu H; Bao Y; Wang X; Zhou D; Wu W
Hum Vaccin Immunother; 2017 Jun; 13(6):1-9. PubMed ID: 28129034
[TBL] [Abstract][Full Text] [Related]
18. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
Tamura S; Ainai A; Suzuki T; Kurata T; Hasegawa H
Jpn J Infect Dis; 2016; 69(3):165-79. PubMed ID: 27212584
[TBL] [Abstract][Full Text] [Related]
19. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
Gupta NK; Tomar P; Sharma V; Dixit VK
Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
[TBL] [Abstract][Full Text] [Related]
20. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
